Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascaline Boudou-Rouquette

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Oncotarget|April 22, 2017
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancersWilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 25, 2019
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patientsAnne Jouinot, Guillaume Ulmann, Clara Vazeille, et al.
British Journal of Cancer|November 2, 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II studyFlorence Duffaud, Jean-Yves Blay, Axel Le Cesne, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
Patient Education and Counseling|September 20, 2024
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide studyElena Paillaud, Angéline Galvin, Solène Doublet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma GroupNicolas Penel, Axel Le Cesne, Sylvie Bonvalot, et al.
Cancer Medicine|December 20, 2022
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma groupMehdi Brahmi, Nathalie Gaspar, Justine Gantzer, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type FibromatosisNicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trialPatricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Oncotarget|April 22, 2017
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancersWilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 25, 2019
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patientsAnne Jouinot, Guillaume Ulmann, Clara Vazeille, et al.
British Journal of Cancer|November 2, 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II studyFlorence Duffaud, Jean-Yves Blay, Axel Le Cesne, et al.
Oncotarget|April 21, 2017
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyMichaël Duruisseaux, Benjamin Besse, Jacques Cadranel, et al.
Patient Education and Counseling|September 20, 2024
Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide studyElena Paillaud, Angéline Galvin, Solène Doublet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2017
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma GroupNicolas Penel, Axel Le Cesne, Sylvie Bonvalot, et al.
Cancer Medicine|December 20, 2022
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma groupMehdi Brahmi, Nathalie Gaspar, Justine Gantzer, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2021
Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II studyFlorence Duffaud, Antoine Italiano, Emannuelle Bompas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2022
Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type FibromatosisNicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, et al.
Pageof 13